ストックスクリーナーアプリを入手
33.01
2.13%
0.69
前日終値:
$32.32
開ける：
$32.8
24時間の取引高:
496.61K
Relative Volume:
0.52
時価総額：
$2.86B
収益：
$4.72M
当期純損益:
$-277.91M
株価収益率:
-8.8499
EPS:
-3.73
ネットキャッシュフロー:
$-203.56M
1週間 パフォーマンス:
+8.19%
1か月 パフォーマンス:
+8.16%
6か月 パフォーマンス:
-43.93%
1年 パフォーマンス:
-27.99%
1日の値動き範囲:
$32.49
$33.32
1週間の範囲:
$30.14
$33.32
52週間の値動き範囲:
$24.10
$62.53
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
名前
Crinetics Pharmaceuticals Inc
セクター
電話
858-450-6464
住所
6055 LUSK BLVD., SAN DIEGO, CA
CRNX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
33.01 | 2.86B | 4.72M | -277.91M | -203.56M | -3.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-25 | 開始されました | Stifel | Buy |
| 2025-02-11 | 開始されました | TD Cowen | Buy |
| 2025-02-04 | 開始されました | Wolfe Research | Peer Perform |
| 2025-01-22 | アップグレード | Jefferies | Hold → Buy |
| 2024-03-06 | 開始されました | Citigroup | Buy |
| 2024-01-16 | 開始されました | Morgan Stanley | Overweight |
| 2023-12-21 | 開始されました | Jefferies | Hold |
| 2023-11-20 | 再開されました | JP Morgan | Overweight |
| 2023-10-24 | 再開されました | Cantor Fitzgerald | Overweight |
| 2023-08-31 | 開始されました | Oppenheimer | Outperform |
| 2023-04-24 | 開始されました | Piper Sandler | Overweight |
| 2023-03-30 | 開始されました | Robert W. Baird | Outperform |
| 2021-11-30 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-11-23 | 開始されました | Evercore ISI | Outperform |
| 2021-06-18 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-12-23 | 開始されました | ROTH Capital | Buy |
| 2019-02-14 | 開始されました | H.C. Wainwright | Buy |
| 2018-08-13 | 開始されました | JP Morgan | Neutral |
| 2018-08-13 | 開始されました | Leerink Partners | Outperform |
| 2018-08-13 | 開始されました | Piper Jaffray | Overweight |
すべてを表示
Crinetics Pharmaceuticals Inc (CRNX) 最新ニュース
(CRNX) Trading Report - news.stocktradersdaily.com
Two Sigma Advisers LP Sells 14,300 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Jane Street Group LLC Sells 122,188 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Thinking Of Buying Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) Stock? Here Is What You Should Know - Stocksregister
H.C. Wainwright maintains Crinetics stock Buy rating, $81 target By Investing.com - Investing.com Canada
H.C. Wainwright maintains Crinetics stock Buy rating, $81 target - Investing.com India
(CRNX) Investment Report - news.stocktradersdaily.com
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Position Lessened by D. E. Shaw & Co. Inc. - Defense World
Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025 | CRNX Stock News - GuruFocus
Crinetics Management Team Set for Key Presentation at Major Jefferies Healthcare Conference - Stock Titan
Bank of America Corp DE Decreases Stock Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
BNP Paribas Financial Markets Cuts Stock Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Crinetics Pharmaceuticals’ SWOT analysis: oral endocrine drug stock poised for growth - Investing.com
Is There An Opportunity With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) 20% Undervaluation? - Yahoo Finance
CRNX Achieves FDA Orphan Drug Status for Paltusotine in Carcinoi - GuruFocus
Is Crinetics Pharmaceuticals, Inc. (CRNX) The Best Stock That Will Bounce Back? - MSN
Crinetics Pharmaceuticals Reports Positive Results for Paltusotine in Treating Surgically Naïve Acromegaly Patients at AACE 2025 - Nasdaq
Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025 - The Manila Times
New Clinical Data: Oral Drug Paltusotine Could Replace Injectable Acromegaly TreatmentsKey AACE 2025 Findings - Stock Titan
Analysts Set Expectations for CRNX FY2025 Earnings - Defense World
Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Crinetics Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q1 2025 Earnings Call Transcript - Insider Monkey
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Tops Revenue Estimates - MSN
Crinetics Pharma’s Earnings Call: Positive Outlook Amid Challenges - TipRanks
Crinetics Pharmaceuticals Inc (CRNX) Q1 2025 Earnings Call Highlights: Strategic Growth and ... - Yahoo Finance
Crinetics Pharmaceuticals Inc (CRNX) Q1 2025 Earnings Call Highlights: Strategic Growth and ... By GuruFocus - Investing.com Canada
Crinetics Pharmaceuticals Inc (CRNX) Q1 2025 Earnings Call Highlights: Strategic Growth and Pivotal Launches on the Horizon - GuruFocus
Earnings call transcript: Crinetics Pharma stock rises after Q1 2025 results - Investing.com Nigeria
Decoding Crinetics Pharmaceuticals Inc (CRNX): A Strategic SWOT Insight - GuruFocus
Crinetics (CRNX) Exceeds Revenue Expectations, Advances Key Proj - GuruFocus
Crinetics Pharmaceuticals Q1 2025 Earnings: Revenue Surpasses Estimates at $0.4M, EPS Misses at -$1.04 - GuruFocus
Crinetics Pharmaceuticals Reports Progress on Paltusotine NDA and Atumelnant Phase 3 Study Amid Strong Financial Position - Nasdaq
Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
11 Stocks That Will Bounce Back According to Analysts - Insider Monkey
Viracta Therapeutics (NASDAQ:VIRX) vs. Crinetics Pharmaceuticals (NASDAQ:CRNX) Head-To-Head Review - Defense World
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
What To Expect From Crinetics Pharmaceuticals Inc (CRNX) Q1 2025 Earnings - GuruFocus
Closing Figures: Crinetics Pharmaceuticals Inc (CRNX)’s Negative Finish at 30.52, Down -9.30 - DWinneX
August 15th Options Now Available For Crinetics Pharmaceuticals (CRNX) - Nasdaq
Crinetics Pharmaceuticals (CRNX) Expected to Announce Earnings on Thursday - Defense World
How To Trade (CRNX) - news.stocktradersdaily.com
Crinetics Pharmaceuticals Inc (CRNX) stock on the rise: An overview - uspostnews.com
Top investors say Crinetics Pharmaceuticals Inc (CRNX) ticks everything they need - Sete News
Recent Insider Activity Suggests Potential Gains for Crinetics Pharmaceuticals Inc (CRNX) - knoxdaily.com
LPL Financial LLC Acquires 1,162 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Market Watch Highlights: Crinetics Pharmaceuticals Inc (CRNX) Ends on an Upturn Note at 33.39 - DWinneX
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Stock Holdings Boosted by Envestnet Asset Management Inc. - Defense World
Crinetics Pharmaceuticals Inc (CRNX) 財務データ
収益
当期純利益
現金流量
EPS
Crinetics Pharmaceuticals Inc (CRNX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Pizzuti Dana | Chief Med and Dev Officer |
Mar 19 '25 |
Sale |
34.20 |
2,515 |
86,021 |
72,233 |
| Knight Jeff E. | Chief Operating Officer |
Mar 19 '25 |
Sale |
34.20 |
7,162 |
244,964 |
87,491 |
| Betz Stephen F. | Chief Scientific Officer |
Mar 19 '25 |
Sale |
34.20 |
5,770 |
197,353 |
108,588 |
| Struthers Richard Scott | President & CEO |
Mar 19 '25 |
Sale |
34.20 |
17,338 |
593,017 |
329,147 |
| Pizzuti Dana | Chief Med and Dev Officer |
Feb 03 '25 |
Option Exercise |
16.89 |
5,000 |
84,450 |
36,748 |
| Pizzuti Dana | Chief Med and Dev Officer |
Feb 03 '25 |
Sale |
39.07 |
5,000 |
195,350 |
31,748 |
1.21%
1.51%
大文字化:
|
ボリューム (24 時間):